YHR112C Antibody

What is YHR112C and why is it relevant for neurodegenerative disease research?

YHR112C is a yeast gene designation within Saccharomyces cerevisiae that has gained relevance in neurodegenerative disease research due to yeast's utility as a model organism. Yeast models have been instrumental in studying proteins involved in human neurodegenerative disorders such as tau (associated with Alzheimer's disease) and alpha-synuclein (associated with Parkinson's disease) . Researchers utilize antibodies against YHR112C to explore protein interactions and pathways that may be conserved between yeast and humans, particularly those related to mitochondrial function, which has been implicated in both tau and alpha-synuclein pathology . The genetic tractability of yeast makes it an excellent system for high-throughput screens to identify modifiers of protein toxicity, as demonstrated in screens for enhancers of tau toxicity and suppressors of alpha-synuclein toxicity .

How are antibody-based detection methods typically validated in yeast models?

Antibody-based detection methods in yeast models require rigorous validation to ensure specificity and reliability. Validation protocols typically include:

• Testing antibody specificity in knockout/deletion strains to confirm absence of signal

• Western blot analysis showing bands of expected molecular weight

• Comparison across multiple antibody clones recognizing different epitopes

• Inclusion of loading controls and standardization markers

• Sarkosyl protein fractionation to distinguish different protein states

Immunoblot optimization is critical, as demonstrated in studies where researchers validated antibody detection of proteins such as the mitochondrial phosphate carrier (PiC) . For example, in tau phosphorylation studies, researchers validate antibodies by confirming detection of specific phosphorylated epitopes (e.g., Ser396/404 or Ser202/Thr205) that are known to be associated with pathological tau states . Similar validation approaches are essential when developing antibodies against yeast proteins such as YHR112C.

What controls should be included when using YHR112C antibodies in immunoblotting experiments?

Robust experimental design for YHR112C antibody immunoblotting should include several critical controls:

Research has shown that inconsistent control usage is a major contributor to irreproducibility in antibody-based research . When designing experiments with YHR112C antibodies, researchers should follow standardized protocols that include these controls, particularly when studying stress responses or protein interactions that may affect expression levels or post-translational modifications.

How should researchers optimize protein extraction protocols for YHR112C detection in yeast?

Optimizing protein extraction for YHR112C detection requires careful consideration of cellular compartmentation and protein characteristics. Based on established yeast protein extraction protocols:

• Cell wall disruption: Mechanical disruption (glass beads or sonication) is preferable to enzymatic methods for preserving protein integrity

• Buffer composition: Include protease inhibitors (complete cocktail) and phosphatase inhibitors if studying phosphorylation states

• Detergent selection: Consider membranous localization - use appropriate detergents (Triton X-100 for membrane-associated proteins)

• Fractionation approach: Implement sarkosyl protein fractionation to separate soluble and insoluble protein pools

For mitochondrial proteins similar to those studied in tau toxicity screens, mitochondrial isolation followed by protein extraction yields better results than whole-cell extracts . The extraction buffer should be optimized based on the cellular localization of YHR112C and its physical properties, with special attention to pH and ionic strength to maintain native conformation for optimal antibody recognition.

How can YHR112C antibodies be used to investigate protein-protein interactions in yeast models of neurodegenerative disease?

YHR112C antibodies can be instrumental in mapping protein interaction networks relevant to neurodegenerative disease models through several advanced approaches:

• Co-immunoprecipitation (Co-IP): YHR112C antibodies can pull down protein complexes, allowing identification of interaction partners. This approach was successful in identifying tau interactions with other proteins in yeast models .

• Proximity-dependent biotin identification (BioID): By fusing YHR112C to a biotin ligase, researchers can identify proximal proteins that become biotinylated, which can then be pulled down and identified by mass spectrometry.

• Fluorescence microscopy with co-localization analysis: As demonstrated in studies of tau and beta-amyloid co-localization, fluorescently tagged antibodies against YHR112C and potential interacting partners can reveal spatial relationships within cells .

• Yeast two-hybrid screening with validation by antibody-based methods: Candidate interactions identified through Y2H can be confirmed using YHR112C antibodies in secondary validation assays.

The ResponseNet approach used for alpha-synuclein toxicity mapping provides a powerful framework for integrating genetic and transcriptional data . This methodology could be adapted for YHR112C studies, with antibody-based validation of the predicted interactions to confirm their biological relevance in the context of cellular stress responses or disease models.

What approaches can resolve epitope masking issues when using YHR112C antibodies in different experimental conditions?

Epitope masking is a significant challenge in antibody-based detection, particularly when protein conformation or interactions change under experimental conditions. Research with CD26 immunophenotyping demonstrates this challenge, where one antibody clone showed dramatic decreases in detection due to epitope masking by another bound antibody . For YHR112C antibody applications:

• Multiple epitope targeting: Develop or use antibodies recognizing different epitopes on YHR112C

• Epitope retrieval methods:

  • Heat-induced epitope retrieval (optimized temperature and buffer conditions)

  • Detergent treatment (SDS, Triton X-100) at calibrated concentrations

  • Reducing agent treatment (DTT or β-mercaptoethanol) for disulfide-dependent masking

• Cross-validation strategies:

  • Test multiple antibody clones in parallel (as demonstrated in CD26 detection studies)

  • Perform competition and cross-blocking experiments with titrated primary antibody

  • Validate results with complementary non-antibody methods (e.g., mass spectrometry)

Validation through careful cross-blocking experiments using increasing dilutions of competing antibodies, as performed in the YS110 clinical trial studies, provides a robust approach to determining whether epitope masking is occurring and which antibody clones provide reliable detection under specific experimental conditions .

How can researchers apply YHR112C antibodies in high-throughput screening approaches?

YHR112C antibodies can be incorporated into high-throughput screening platforms using these methodologies:

• Automated immunofluorescence microscopy: Similar to screens counting cells with protein inclusions in tau-expressing yeast , automated microscopy platforms can quantify YHR112C localization, abundance, or modification state across thousands of genetic backgrounds or compound treatments.

• Flow cytometry-based screening: For detecting YHR112C in intact cells, particularly when studying surface-exposed epitopes or using permeabilization protocols.

• ELISA-based drug discovery platforms: Following the model of the "mir1Δ-tau40 drug discovery platform" described in the tau toxicity studies , researchers can develop ELISA systems using YHR112C antibodies to screen compound libraries.

• Protein microarrays: YHR112C antibodies can be used in reverse-phase protein arrays to assess protein levels across multiple samples simultaneously.

The screening of marine bacteria extracts for suppressors of tau toxicity provides a template for similar approaches with YHR112C . Integration with the yeast knockout (YKO) collection enables powerful genetic interaction mapping, as exemplified by the tau toxicity enhancer screen that identified 31 genes forming a framework for understanding tau pathology mechanisms .

How should researchers address variability in YHR112C antibody-based assays when comparing results across experiments?

Addressing variability in antibody-based assays requires systematic approaches to normalization and standardization:

• Standard curve inclusion: Include a dilution series of purified YHR112C protein in each experiment to generate standard curves

• Internal reference controls: Use consistent positive and negative controls across all experimental batches

• Statistical normalization approaches:

  • Apply appropriate transformation methods based on data distribution

  • Use mixed-effects models to account for batch variation

  • Implement Bayesian hierarchical modeling for complex experimental designs

• Metadata documentation: Record and report all relevant experimental parameters:

  • Antibody lot number and source

  • Incubation times and temperatures

  • Buffer compositions and pH

  • Sample preparation procedures

The Johns Hopkins study on immunohistochemical staining variability highlights that inconsistencies in antibody usage continue to undermine experimental reproducibility . Researchers working with YHR112C antibodies should implement standardized protocols with detailed documentation of all variables that may affect antibody performance.

What approaches can integrate antibody-based YHR112C data with other -omics datasets?

Multi-omics integration with antibody-based YHR112C data can provide comprehensive understanding of biological systems:

• Transcriptome-proteome correlation: Compare YHR112C protein levels (detected by antibodies) with YHR112C mRNA expression levels to identify post-transcriptional regulation mechanisms. This approach revealed interesting patterns in HSP90 isoform expression during stress responses in yeast .

• Network integration algorithms: Apply methods like ResponseNet, which successfully bridged genetic and transcriptional data in alpha-synuclein toxicity studies , to connect YHR112C antibody-derived protein data with genetic interaction networks.

• Translational efficiency analysis: Combine polysomal mRNA profiling with YHR112C protein quantification to assess translational regulation, as demonstrated in studies of HSP90 isoforms that revealed IRES-mediated translation during stress .

• Statistical integration frameworks:

The integration of genetic screen data with transcriptional profiling, as demonstrated in the alpha-synuclein studies, provides a powerful template for similar multi-omics approaches with YHR112C .

How can YHR112C antibodies be adapted for studying protein dynamics in live yeast cells?

Studying protein dynamics in live cells requires specialized adaptations of traditional antibody approaches:

• Antibody fragment technology: Convert conventional YHR112C antibodies to smaller formats:

  • Single-chain variable fragments (scFv)

  • Antigen-binding fragments (Fab)

  • Nanobodies derived from camelid antibodies

• Cell-penetrating peptide conjugation: Attach cell-penetrating peptides (CPPs) to YHR112C antibodies or fragments to facilitate entry into live yeast cells.

• Intracellular expression of antibody-based sensors:

  • Express fluorescently-tagged intrabodies specific to YHR112C

  • Develop split-GFP complementation systems where one fragment is fused to an anti-YHR112C intrabody

• Correlative approaches: Combine live cell measurements with fixed cell antibody-based detection:

  • Use photoconvertible fluorescent proteins fused to YHR112C

  • Apply antibody staining after live imaging to correlate dynamic and molecular information

These approaches build upon imaging techniques used in tau and alpha-synuclein studies, where fluorescence microscopy was employed to count cells with protein inclusions and assess protein localization patterns . The challenge with live cell applications is maintaining yeast cell wall integrity while allowing antibody access, which requires careful optimization of permeabilization conditions or genetic engineering of the cell wall.

What are the best practices for using YHR112C antibodies in studies of post-translational modifications?

Detection of post-translational modifications (PTMs) on YHR112C requires specialized antibody approaches:

• Modification-specific antibodies: Develop antibodies that specifically recognize:

  • Phosphorylated epitopes (similar to AT8-tau antibody that recognizes phosphorylation at Ser202/Thr205)

  • Acetylated lysine residues

  • Ubiquitinated lysine residues

• Enrichment strategies prior to antibody detection:

  • Phosphopeptide enrichment using titanium dioxide (TiO₂) or immobilized metal affinity chromatography (IMAC)

  • Ubiquitinated protein enrichment using tandem ubiquitin binding entities (TUBEs)

• Validation of PTM-specific antibodies:

  • Use genetic mutants lacking the modifying enzyme

  • Create site-directed mutants of the modification site

  • Compare detection before and after treatment with specific demodifying enzymes (phosphatases, deacetylases)

• Quantitative analysis of modification stoichiometry:

  • Use a combination of modification-specific and total protein antibodies

  • Apply mass spectrometry validation of antibody-detected modifications

Studies of tau phosphorylation in yeast models demonstrate how modification-specific antibodies (such as those recognizing phosphorylation at Ser396/404) can provide insights into regulatory mechanisms, including the role of specific kinases like GSK-3β . Similar approaches can be applied to study YHR112C modifications under various cellular conditions or genetic backgrounds.

What emerging technologies might enhance YHR112C antibody applications in yeast research?

Several cutting-edge technologies are poised to revolutionize antibody applications in yeast research:

• Proximity labeling methods: BioID or TurboID fusion to YHR112C combined with antibody-based detection of biotinylated proteins can map protein neighborhoods in living cells.

• Super-resolution microscopy: Techniques such as STORM, PALM, or expansion microscopy combined with highly specific YHR112C antibodies can resolve protein localization at nanometer-scale resolution.

• Single-molecule tracking: Using quantum dot-conjugated antibody fragments to track individual YHR112C molecules in living yeast cells.

• Spatial transcriptomics integration: Correlating YHR112C protein localization (by antibody detection) with spatial mRNA expression patterns.

• Deep learning image analysis: Applying neural networks to analyze complex patterns in YHR112C immunofluorescence data, similar to automated counting of cells with protein inclusions .

• Microfluidic antibody-based assays: Developing lab-on-a-chip platforms for real-time monitoring of YHR112C expression or modification in response to environmental perturbations.

These emerging technologies build upon established yeast model systems that have already proven valuable for studying human disease-related proteins and promise to further enhance our understanding of fundamental biological processes and disease mechanisms.